Advertisement


David Routman, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV Circulating Tumor DNA

2019 ASTRO Annual Meeting

Advertisement

David Routman, MD, of the Mayo Clinic, discusses his study findings showing that detectable human papillomavirus circulating tumor DNA in the postoperative setting may be linked to disease progression, which may help improve patient selection for treatment intensity (Abstract LBA5).



Related Videos

CNS Cancers

Erica H. Bell, PhD, on Low-Grade Gliomas: Subgroup Analysis of the NRG Oncology/RTOG 9802 Trial

Erica H. Bell, PhD, of The Ohio State University, discusses phase III findings from a prognostic and predictive molecular subgroup analysis of radiotherapy vs radiotherapy pl...

Prostate Cancer

Andrew Kneebone, MD, on an ANZUP Trial on Adjuvant vs Early Salvage Radiotherapy After Prostatectomy

Andrew Kneebone, MD, of Royal North Shore Hospital, discusses phase III study findings showing that at 5 years, biochemical control was similar between adjuvant and early sal...

Prostate Cancer

Ryan Phillips, MD, PhD, on Oligometastatic Prostate Cancer: ORIOLE Trial on Observation vs Stereotactic Ablative Radiation

Ryan Phillips, MD, PhD, of Johns Hopkins Medical Institutions, discusses phase II findings suggesting that treatment with stereotactic ablative radiation significantly decrea...

Head and Neck Cancer

Sue Sun Yom, MD, PhD, on Oropharyngeal Cancer: Deintensifying Radiation Therapy Plus Chemotherapy

Sue Sun Yom, MD, PhD, of the University of California, San Francisco, discusses phase II results showing that swallowing-related quality of life after deintensified chemoradi...

Issues in Oncology
Solid Tumors

Daniel M. Trifiletti, MD, on Optimizing Whole-Brain Radiotherapy Dose and Fractionation for Patients With Brain Metastases

Daniel M. Trifiletti, MD, of the Mayo Clinic, discusses study findings showing that, between two different radiation doses (30 Gy/10 fractions vs 37.5 Gy/15 fractions), there...

Advertisement

Advertisement



Advertisement